IMRN (Immuron Ltd) Forward P/E Multiple

Corporate emblem and logo of immuron.com.au (IMRN)

Immuron Limited is developing its mature Travelan product line by expanding its sales markets. Growth is supported by R&D contracts with the US Army to create hyperimmune milk. The company's forward P/E dynamics reflect the real-time valuation of the business, with the value stabilizing at 0.00. However, fierce competition for pharmacy shelf space with dietary supplement and probiotic manufacturers creates significant risks for the brand's expansion.

IMRN - Immuron Market Cap to Projected Earnings over the range 07/04/2022 - 11/10/2026

Analytical breakdowns and data insights for company Immuron Inc (IMRN)

- current price and projected stock value:
Stock Quotes Immuron Limited|IMRN - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Immuron Ltd|IMRN - Full Takeover Company Value
- book capitalization information:
Book Value per Share Immuron|IMRN - Book Valuation of Business|Market Cap to Net Assets Ratio immuron.com.au|IMRN - Aggregate Business Assets
- debt and liquidity data:
Total Debt to Capital Immuron Limited|IMRN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Immuron Limited|IMRN - Company Total Debt|Debt to Book Capitalization Ratio Immuron Ltd|IMRN - Company Long-Term Liabilities|Company Current Liabilities Immuron|Quick Liquidity immuron.com.au
- earnings and market ratios statistics:
IMRN - Final Profit|Expected Profit Immuron Limited|IMRN - Market Cap to Earnings|Future Price to Earnings Immuron Limited|IMRN - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Immuron Ltd|IMRN - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Immuron|IMRN - Earnings per share for the last twelve months|Quarterly EPS earnings growth immuron.com.au|IMRN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Immuron Limited
Fundamental company analysis:IMRN Immuron
Brand item of Immuron Limited

Immuron Limited revenues depend on global tourism flows and the efficiency of distributing antibacterial drugs through pharmacy retail. The ratio of the current share price to projected earnings allows for an assessment of the premium paid for future business success; therefore, the company's future P/E trajectory serves as an indicator of the balance between market expectations and the issuer's actual ability to generate cash flow.

Competitors of Immuron Limited

Projected Price to Earnings PHAT (Phathom Pharmaceuticals, Inc.)|TERN (Terns Pharma) - Future Price to Earnings Multiple|Forward P/E Multiple IRWD (Ironwood Pharmaceuticals, Inc.)|Forward Price to Earnings Multiple Curanex Pharma|Evoke Pharma, Inc. - Forward P/E Multiple|Market Cap to Projected Earnings Entero Therapeutics, Inc. ENTO|RDHL (redhillbio.com) - Projected Price to Earnings|PALI: Market Cap to Future Earnings Ratio|JAGX (Jaguar Animal Health) - Forward P/E Multiple|Biora Therapeutics, Inc (BIOR) - Market Cap to Projected Earnings|Future Price to Earnings Morphic Holding, Inc. (MORF)